Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Partner Haisco received marketing approval from China's NMPA for Ciprocopan (NXP100) as a first-in-class once-daily oral Factor B inhibitor for treatment-naive PNH patients. The approval was supported by a Phase 3 head-to-head study demonstrating superiority to Soliris, including significantly higher hemoglobin response rates (59.5% vs 8.3%) and reduced transfusion requirements.
Key figures
- Drug Name
- Ciprocopan (NXP100)
- Phase Of Trial
- Phase 3
- Hb target soliris pct
- 8.3
- Hb increase soliris gdl
- 2.2 g/dL
- Hb target ciprocopan pct
- 59.5
- Hb increase ciprocopan gdl
- 5.0 g/dL
- Transfusion free soliris pct
- 69.4
- Transfusion free ciprocopan pct
- 94.6
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.